Showing 1491-1500 of 1644 results for "".
- Long-Term Seizure Reduction Seen with 5-HT2C Receptor Superagonist Treatment in Those with DEEshttps://practicalneurology.com/news/treatment-with-bexicaserin-associated-with-seizure-frequency-reduction-for-people-with-developmental-and-epileptic-encephalopathies/2473786/Treatment of seizures using bexicaserin (Lundbeck, Deerfield, IL) was associated with improved long-term efficacy, safety, and tolerability outcomes for individuals with developmental and epileptic encephalopathies (DEEs) in the results of a 12-month open-label extension (OLE) study. Individuals
- Beta-Blocker Shows Promise in Reducing Stroke Risk for Women with Migrainehttps://practicalneurology.com/news/beta-blocker-shows-promise-in-reducing-stroke-risk-for-women-with-migraine/2473779/Treatment with propranolol for women with migraine may reduce risk of stroke, according to findings from a preliminary study of 3 million electronic health records (EHRs) presented at the American Stroke Association’s International Stroke Conference 2025. Propranolol, a nonselective beta-bl
- Biomarker Testing May Accelerate Synucleinopathy Diagnosis According to New CNSA White Paperhttps://practicalneurology.com/news/biomarker-testing-may-accelerate-synucleinopathy-diagnosis-according-to-new-cnsa-white-paper/2473772/The emergence of new biomarker tests may enable earlier detection and treatment of symptoms associated with synucleinopathies according to a new comprehensive Clinical Proceedings White Paper published by the Clinical Neurological Society of America (CNSA). The White Paper, titled &ldqu
- Gabapentin Users Experienced Fewer Falls than Duloxetine Usershttps://practicalneurology.com/news/gabapentin-users-experienced-fewer-falls-than-duloxetine-users/2470943/Treatment with gabapentin may be associated with a reduced risk of falls compared with duloxetine, according to study results published in the Annals of Internal Medicine. Gabapentin users demonstrated significantly fewer fall-related healthcare visits compared with duloxetine users and an approx
- Rapid Response EEG Shows Class II Evidence for Reliably Detecting Status Epilepticushttps://practicalneurology.com/news/rapid-response-eeg-shows-class-ii-evidence-for-reliably-detecting-status-epilepticus/2470941/A study published in Neurology has provided Class II evidence demonstrating the reliability of automated seizure burden estimator (ASBE) software associated with rapid response EEG (rr-EEG) used in screening for electrographic status epilepticus (ESE) without the need for expert review. The findi
- Underrepresentation in Epilepsy Genome Studies May Increase Health Disparitieshttps://practicalneurology.com/news/underrepresentation-in-epilepsy-genome-studies-may-increase-health-disparities/2470651/Study results presented at the American Epilepsy Society (AES) 2024 Annual Meeting showed a significant lack of diversity in epilepsy genome-wide association studies (GWAS). Most of the participants in these studies were of European ancestry, with an underrepresentation of participants of East As
- Ingrezza Treatment for Tardive Dyskinesia Improved Functional, Social, Emotional, and Health-Related Quality of Life Measureshttps://practicalneurology.com/news/ingrezza-treatment-for-tardive-dyskinesia-improved-functional-social-emotional-and-health-related-quality-of-life-measures/2470633/Treatment with Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) was associated with improvements in functional, social, emotional, and health-related quality of life measures for people with tardive dyskinesia (TD). The findings of 3 separate analyses of clinical study and survey dat
- Insights into Tardive Dyskinesia and Chorea Treatment with Austedo and Austedo XR Reported at Psych Congress 2024https://practicalneurology.com/news/insights-into-tardive-dyskinesia-and-chorea-treatment-with-austedo-and-austedo-xr-reported-at-psych-congress-2024/2470630/The majority of people with TD or chorea associated with Huntington disease (HD) who were treated with Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) reported a reduction in extra movement after treatment and satisfaction with the medication, according to real-world patient exp
- AGED Triad of Vascular Aging Linked to Biomarkers of Alzheimer Diseasehttps://practicalneurology.com/news/aged-triad-of-vascular-aging-linked-to-biomarkers-of-alzheimer-disease/2470625/The AGED triad (apathy, gait disturbances, and executive dysfunction), a vascular aging phenotype associated with mood, mobility, and cognitive impairment, has been linked to biomarkers of Alzheimer disease (AD) according to a study presented at the 17th annual Clinical Trials on Alzheimer’
- Favorable Results for Radiprodil Tx for GRIN Disorders Leads to Launch of Study to Test Treatment in Those with Tuberous Sclerosis or Focal Cortical Dysplasiahttps://practicalneurology.com/news/favorable-results-for-radiprodil-tx-for-grin-disorders-leads-to-launch-of-study-to-test-treatment-in-those-with-tuberous-sclerosis-or-focal-cortical-dysplasia/2470617/Treatment with radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), was well tolerated and associated with a significant reduction in seizure frequency in children with GRIN-related neurod